8-K
filed February 13, 2026, 6:59 PM ET
ticker BCLI
CIK 0001137883
other material
confidence high
sentiment neutral
materiality 0.50
Brainstorm Cell Therapeutics raises $1M in private placement at $0.60 per share
BRAINSTORM CELL THERAPEUTICS INC.
- Entered Securities Purchase Agreement for $1M total, closings of $500k each on Feb 9, 2026 and ~30 days later.
- Investor receives common stock or pre-funded warrants at $0.60 and common warrants for 120% of shares at $1.00 exercise price.
- First closing occurred on February 9, 2026; second closing subject to conditions.
- Net proceeds for working capital; registration statement to be filed within 45 days.
- Issuance exempt under Section 4(a)(2) and Regulation D; OTCQB ticker BCLI.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. issued common stock to accredited investor for $0.60 per share.
- Security
- common stock
- Purchaser
- accredited investor
- Consideration
- $0.60 per share
Exact text from the filing
subscription amount under the Purchase Agreement is $1,000,000, consisting of $500,000 at the first closing and $500,000 at the second closing. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. issued a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor of warrant to accredited investor.
- Security
- warrant
- Shares
- a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor
- Purchaser
- accredited investor
Exact text from the filing
exercisable for a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor, with an exercise price of $1.00 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. issued warrant to accredited investor for $0.60 less $0.0005 per Pre-Funded Warrant.
- Security
- warrant
- Purchaser
- accredited investor
- Consideration
- $0.60 less $0.0005 per Pre-Funded Warrant
Exact text from the filing
subscription amount under the Purchase Agreement is $1,000,000, consisting of $500,000 at the first closing and $500,000 at the second closing. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an accredited investor
- Value
- $1,000,000
- Effective
- 2026-02-09
Exact text from the filing
On February 9, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.